Forecasting PARP Inhibitor Resistance in Breast Cancer Patients

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Priya Jayachandran, MD, FACP, spoke about her new position at El Camino Health as well as her career as a breast oncologist.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD

Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

Russ Conroy

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

Roman Fabbricatore

Strategizing ADC Use to Enhance Breast Cancer Outcomes

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

Breast Medical Oncologist Returns Home to Serve in Multidisciplinary Clinic

Paolo Tarantino, MD, PhD, discusses sequencing ADCs, managing cross-resistance, and understanding ADC composition for patients with breast cancer.

Related Content

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Priya Jayachandran, MD, FACP, spoke about her new position at El Camino Health as well as her career as a breast oncologist.

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD

Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Russ Conroy

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Roman Fabbricatore

Strategizing ADC Use to Enhance Breast Cancer Outcomes

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.